# Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke

> **NCT03993236** · PHASE4 · COMPLETED · sponsor: **Keun-Sik Hong** · enrollment: 584 (actual)

## Conditions studied

- Stroke, Ischemic

## Interventions

- **DRUG:** Experimental: Rosuvastatin/Ezetimibe 10
- **DRUG:** Active Comparator: Rosuvastatin 20mg

## Key facts

- **NCT ID:** NCT03993236
- **Lead sponsor:** Keun-Sik Hong
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-09
- **Primary completion:** 2021-09-27
- **Final completion:** 2021-09-27
- **Target enrollment:** 584 (ACTUAL)
- **Last updated:** 2024-10-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03993236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03993236, "Study on Rosuvastatin+Ezetimibe and Rosuvastatin for LDL-C Goal in Patients With Recent Ischemic Stroke". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03993236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*